ოთხშაბათი, აპრილი 15, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Metabolic

D-Mannose

D-Mannose

Also known as: D-mannose, mannose, carbohydrate urinary supplement

LOW RISK 2.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.5/10).

02

Safety Profile

Known Safety Concerns

  • Raises blood glucose -- relevant for diabetics
  • Should not replace antibiotic treatment for complicated UTIs
  • Higher doses cause osmotic diarrhoea
  • Very large doses may be gluconeogenic

Contraindications

  • Raises blood glucose -- relevant for diabetics
  • Should not replace antibiotic treatment for complicated UTIs
═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

D-mannose is a simple sugar used for urinary tract infection (UTI) prevention and recurrence reduction. It inhibits E. coli adhesion to urinary tract epithelium. Clinical evidence for prevention of recurrent UTIs is moderately positive. Raises blood glucose. Should not replace antibiotic treatment for active UTI in high-risk individuals.

Classification

Biological and Chemical Classification

Scientific Name
D-Mannose
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Metabolic
Key Safety Concern Raises blood glucose -- relevant for diabetics
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Metabolic
Main Safety Concern Raises blood glucose -- relevant for diabetics
Ingredient D-Mannose
Scientific name D-Mannose
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Metabolic
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • Raises blood glucose -- relevant for diabetics
  • Should not replace antibiotic treatment for complicated UTIs
  • Higher doses cause osmotic diarrhoea
  • Very large doses may be gluconeogenic
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for D-Mannose indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient D-Mannose
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name D-Mannose
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 25 მარ 2026, 17:57

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Development of a cold-adapted enzymatic cascade system for in situ value-added conversion of milk. ↗
    PMID 41871497 ↗
    Journal Food Chem
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41871497/
    Zeng Q et al.. Development of a cold-adapted enzymatic cascade system for in situ value-added conversion of milk.. Food Chem. 2026. PMID:41871497.
  2. Observational / other LOW evidence YELLOW
    Synthesis of 3u2011Cu2011Methylu2011du2011Mannopyranoside Derivatives Functionalized at the 3u2011Position. ↗
    PMID 41799092 ↗
    Journal ACS Omega
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41799092/
    Abdullayev S et al.. Synthesis of 3u2011Cu2011Methylu2011du2011Mannopyranoside Derivatives Functionalized at the 3u2011Position.. ACS Omega. 2026. PMID:41799092.
  3. Observational / other LOW evidence YELLOW
    Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy. ↗
    PMID 41791502 ↗
    Journal Brain Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41791502/
    Patel S et al.. Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy.. Brain Res. 2026. PMID:41791502.
  4. Observational / other LOW evidence YELLOW
    Sporolactobacillus fermentans sp. nov., an obligately anaerobic and lactic acid bacterium isolated from pit mud. ↗
    PMID 41770425 ↗
    Journal Antonie Van Leeuwenhoek
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41770425/
    Ye G et al.. Sporolactobacillus fermentans sp. nov., an obligately anaerobic and lactic acid bacterium isolated from pit mud.. Antonie Van Leeuwenhoek. 2026. PMID:41770425.
  5. Observational / other LOW evidence YELLOW
    Tissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability. ↗
    PMID 41745578 ↗
    Journal Metabolites
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41745578/
    Onluturk Aydogan O et al.. Tissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability.. Metabolites. 2026. PMID:41745578.
  6. Observational / other LOW evidence YELLOW
    A randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women. ↗
    PMID 41743922 ↗
    Journal Curr Urol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41743922/
    Singh RG et al.. A randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women.. Curr Urol. 2026. PMID:41743922.
  7. Observational / other LOW evidence YELLOW
    Synthesis of N-substituted 2-carboxamido azasugars via sequential Ugi-3CR/cyclization reaction. ↗
    PMID 41723923 ↗
    Journal Carbohydr Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41723923/
    Luo H et al.. Synthesis of N-substituted 2-carboxamido azasugars via sequential Ugi-3CR/cyclization reaction.. Carbohydr Res. 2026. PMID:41723923.
  8. Observational / other LOW evidence YELLOW
    Microplastics and Nitrite Stress Affect Physiological and Metabolic Functions of the Hepatopancreas in Marine Shrimp. ↗
    PMID 41718265 ↗
    Journal J Xenobiot
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41718265/
    Xing YF et al.. Microplastics and Nitrite Stress Affect Physiological and Metabolic Functions of the Hepatopancreas in Marine Shrimp.. J Xenobiot. 2026. PMID:41718265.
  9. Observational / other LOW evidence YELLOW
    The responses of rice plant to tricyclazole at the transcriptome and metabolome levels. ↗
    PMID 41710179 ↗
    Journal Front Plant Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41710179/
    Huang W et al.. The responses of rice plant to tricyclazole at the transcriptome and metabolome levels.. Front Plant Sci. 2026. PMID:41710179.
  10. Observational / other LOW evidence YELLOW
    Primary Care Provider Practice Patterns in the Management of Recurrent UTI. ↗
    PMID 41811789 ↗
    Journal Urogynecology (Phila)
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41811789/
    Tholemeier LN et al.. Primary Care Provider Practice Patterns in the Management of Recurrent UTI.. Urogynecology (Phila). 2025. PMID:41811789.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 2.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.5 / 10

Final GIRI Score for D-Mannose. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 2.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
2.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for D-Mannose

GIRI Score 2.5 / 10

A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge